3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The proposed 36-month Post Approval Efficacy Study (PAES) is a prospective, interventional, multicentre study to explore the long-term evolution of signs and symptoms, and occurrence of complications in Dry Eye Disease (DED) patients with severe keratitis receiving Ikervis® (1mg/mL ciclosporin) eye drops administered once daily
Epistemonikos ID: f95bae18c1fba615e90386be77e82f90a5d823a7
First added on: May 06, 2024